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Abstract
Background and Objectives Multiple sclerosis (MS) is the
most common inflammatory disease of the central nervous
system in young adults. Over time, the disease progresses and,
with accumulating disability, symptoms such as spasticity
may occur. Although several treatment options are available,
some patients may not respond to first-line therapeutics.
However, some of these patients may benefit from intrathe-
cally administered triamcinolone-acetonide (TCA), a deriva-
tive of glucocorticosteroids (GCS). GCS may have neurotoxic
effects, and cell apoptosis may occur. The aim of this study
was to investigate the effects of TCA on biomarkers in the
cerebrospinal fluid (CSF) suggestive of neurodegeneration.
Methods In order to assess neurotoxic effects of TCA,
neurofilament heavy-chain (NfH)SMI35, tau protein, and
S-100B protein levels were determined before and during
treatment with TCA in 54 patients with primary progres-
sive MS, as well as relapsing MS (relapsing–remitting and
secondary progressive MS).
Results NfHSMI35 levels in the CSF of patients treated with
TCA intrathecally did not increase significantly during the
treatment cycle (p = 0.068). After application of TCA, tau
protein levels were increased significantly at day 4 (p = 0.03)
and at day 8 (p B 0.001). S-100B protein levels decreased
significantly (p B 0.05) during treatment with TCA.
Conclusion NfHSMI35 levels did not change significantly;
however, tau protein levels did increase significantly within
the reference range. Taking these findings together, the
long-term effects of TCA on NfHSMI35 and tau protein
levels need to be investigated further to understand whether
levels of both biomarkers will change over repeated TCA
applications. Interestingly, S-100B protein levels decreased
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significantly during the first applications, which may have
represented reduced astrocytic activity during TCA treatment.
Key Points
Short-term intrathecal triamcinolone-acetonide
(TCA) treatment significantly influences levels of
two proteins expressed by astroglia: S-100B and tau
protein, suggesting reduction of astrocytic activation
In this study, short-term intrathecal TCA treatment
did not change neurofilament heavy-chain levels,
suggesting the absence of a major neuroprotective
treatment effect
Future treatment trials may investigate whether
hyperacute treatment with intrathecal TCA may
reduce the inflammatory component of glia in the
setting of severe transverse myelitis in multiple
sclerosis and possibly also neuromyelitis optica
spectrum disorders, and thus improve the clinical
outcome
1 Introduction
Multiple sclerosis (MS) is the most common inflammatory
disease of the central nervous system in young adults [1]. The
estimated worldwide prevalence of MS is 2.1 million people
[2]. Over time, the disease disability accumulates, and most
patients may enter ongoing progression (progressive MS),
whereas acute exacerbation may become less likely [3]. With
accumulating disability, patients may suffer from spasms.
Consequently, patients report impaired walking and may
experience other symptoms, such as unpleasant sensations,
pain, and incontinence [4]. Symptomatic treatment is essen-
tial for these symptoms. Besides impaired quality of life,
spasticity represents a tremendous cost factor. A study in
Sweden revealed that annual costs are 2.4 times higher in
patients with severe spasticity than in those with only mild
spasticity [5–7]. Spasmolytic therapeutics taken orally may
have systemic side effects, and thus their usage is limited.
Intrathecal baclofen therapy and baclofen pumps offer a way
to deal with spasticity, but besides the cost factors, systemic
side effects and infections are common [8].
Intrathecally applied glucocorticosteroids (GCS) have
been used since the 1950s. As therapeutic agents, hydro-
cortisone and methylprednisolone acetonide have been
used but failed to show immunomodulatory effects on the
course of disease. Side effects such as urinary inconti-
nence, constrictive arachnoiditis, aseptic meningitis, and
spinal cord lesions have been reported. However, positive
effects on spasticity, with improvement of walking, have
also been reported. A number of monocentric trials have
shown positive effects of intrathecal GCS application on
spasticity [9–12]. Intrathecal therapy with triamcinolone-
acetonide (TCA), a derivative of GCS, has been shown to
be safe, and no severe side effects have occurred [13].
Intrathecally applied GCS seems to have positive effects on
spasticity and may spare MS patients the discomfort of
wearing a corset.
Nevertheless, in vitro studies have shown that GCS may
induce apoptosis in neuronal cells [14, 15]. This hypothesis
is supported by observations in vivo [16]. It is unclear
whether GCS or its additives may induce cell injury [17].
There is therefore a need to investigate the effects of
intrathecal GCS on neurodegenerative markers in the
cerebrospinal fluid (CSF) to address this issue.
Neurofilaments are a highly specific component of the
axoskeleton and are released during axonal damage. Neu-
rofilament heavy-chain (NfH) levels in body fluids are an
established marker for estimation of axonal damage in a
range of neurological disorders [18].
Tau protein, as a phosphorylated microtubule-associated
protein, is known as a component of neuronal axons.
Released into the CSF, it may serve as a biomarker of
axonal damage, as shown by previous studies [19–21].
S-100B is a multigenic family of calcium-binding pro-
teins found in astrocytes. Several studies have suggested
that these proteins might play a certain role in the regula-
tion of effector proteins and may influence specific parts of
signaling pathways or cellular functions. S-100B proteins
seem to possess both neuroprotective and neurotoxic
properties, and have been used as a marker of astrocytic
proliferation and gliosis [21–23].
The effects of TCA treatment are complex, and its
pharmacodynamic effects on tau protein, S-100B, and
NfHSMI35, as potential predictors of axonal degeneration,
glial activation, and astrogliosis in MS patients, have not
been extensively characterized.
This prospective study aimed to investigate the effects
of repeated TCA applications on the CSF markers sug-
gestive of neurodegeneration: tau protein, S-100B, and
NfHSMI35 in MS patients with severe spasticity.
2 Material and Methods
2.1 Patients
Fifty-four patients suffering from MS, according to the
McDonald criteria [24], were consecutively recruited to
participate in this multicentre study (see Table 1). All
patients were clinically stable (i.e. they had experienced no
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relapse or recent progression over the previous 3 months) and
were not receiving other immunomodulating or immuno-
suppressive treatment. Two thirds of the included patients
were female and were in the progressive stage of MS. Sta-
tistical analyses revealed a non-normal distribution, accord-
ing to the Kolmogorov–Smirnov test (see Table 1).
All patients gave written and informed consent for
participation in the trial, which was approved by the local
ethics committee at the University of Rostock (Rostock,
Germany) and registered with the German Clinical Trials
Register (DRKS; registration no. DRKS00005671) [see
http://www.drks.de and http://www.who.int/ictrp/en].
2.2 Procedures
Every second day, TCA was applied intrathecally.
Depending on the spasticity, the dosage ranged from 40 mg
to 80 mg. Furthermore, the applications were done three
times or, in cases with severe spasticity, five times over the
course of a week. TCA treatments were performed on days
0, 2, and 4 (in patients receiving three applications) and
additionally on days 6 and 8 in those receiving five
applications. In 26 patients, TCA was administered five
times, whereas treatment was terminated after three
applications in 28 patients because a sufficient antispastic
effect had been achieved. The mean dosages over the cycle
were 127.4 mg (standard deviation [SD] 22.3) in patients
receiving three applications and 205.9 mg (SD 37.3) in
those receiving five applications.
All lumbar punctures were performed as per routine
clinical practice for therapeutic purposes only. Because of
the invasiveness of the therapy, no CSF from control
subjects was obtained. Sprotte cannulas (Pajunk Medi-
zintechnologie GmbH, Geisingen, Germany) were used for
obtaining CSF. After each lumbar puncture, CSF was
obtained in 10 ml polypropylene tubes and stored within
30 min in 1 ml aliquots at -70 C.
2.3 Laboratory Analyses
The routine parameters of the CSF, including the cell count,
total protein, albumin, lactate, quantitative immunoglobulin
(Ig)-G, and oligoclonal IgG bands (OCB), were quantified
in the local laboratories at each centre. CSF protein bio-
markers were quantified in dedicated laboratories (tau
protein and S-100B in Ulm, Germany; NfHSMI35 in Lon-
don, UK). Cell-free CSF was shipped on dry ice and kept
frozen on arrival without interruption of the cooling
chain.
2.3.1 Measurement of Neurofilament (NfHSMI35)
The original method has previously been described in
detail [18]. In brief, immunoassays were performed for
quantification of NfH. Mouse monoclonal anti-NfH anti-
body SMI35R was used for capture (Covance, Princeton,
NJ, USA), rabbit polyclonal anti-NfH was used as the
detecting antibody (Sigma-Aldrich, St. Louis, MO, USA),
and horseradish-labeled swine polyclonal anti-rabbit anti-
body was used as the indicator antibody (Dako, Copenha-
gen, Denmark).
Chemicals were obtained from Sigma-Aldrich (ethyle-
nediaminetetraacetic disodium salt [EDTA], sodium bar-
bitone, sodium carbonate [Na2CO3], sodium hydrogen
carbonate [NaHCO3], Tween 20 [soap], bovine serum
albumin [BSA]), from Merck (Darmstadt, Germany;
hydrochloric acid [HCl]), and from Dako (tetramethyl-
benzidine [TMB]). For analysis, MaxiSorp microtiter
plates (Life Technologies, Paisley, Scotland) were used.
2.3.2 Measurement of Tau Protein
Tau protein levels were determined using a commercial
sandwich enzyme-linked immunosorbent assay (ELISA)
[InnoTest hTau; Innogenetics, Zwijndrecht, Belgium]
based on the original method of Vandermeeren [25].
The assay was performed according to the protocol sup-
plied with the kit, and CSF tau protein levels in the samples
were estimated from standard curves made for each assay.
2.3.3 Measurement of S-100B Protein
S-100B protein levels were measured by means of an im-
munoluminometric assay kit (LIA-mat Sangtec 100;
Table 1 Patient characteristics
MS multiple sclerosis,
SD standard deviation
Characteristic All patients Female patients Male patients
Patients (n) 54 36 18
Age (years ± SD) 47.9 ± 9.7 48.7 ± 9.7 46.2 ± 9.9
Course of disease (n)
Relapsing MS–remitting MS 46 33 13
Primary progressive MS 8 3 5
Age at onset of disease (years ± SD) 35.1 ± 8.7 35.5 ± 8.8 34.4 ± 8.8
Disease duration (years ± SD) 12.4 ± 8.4 13.0 ± 8.5 11.3 ± 8.1
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AB Sangtec, Bromma, Sweden), which measures the
b subunit of S-100B protein [26]. The assay was performed
according to the manufacturer’s protocol.
2.4 Statistical Analyses
Statistical analyses were performed with SPSS ver-
sion 15.0 (Chicago, IL, USA) and IBM SPSS Statistics
version 20 software (Armonk, NY, USA). The Kolmogo-
rov–Smirnov test was used for checking the distribution of
all parameters. The collected data did not follow normal
distribution. CSF parameters, socio-demographic parame-
ters, and clinical parameters were analyzed with the Krus-
kal–Wallis one-way analysis of variance and the Mann–
Whitney U test. For analysis over the course of time, the
Friedman test and the Wilcoxon t test were used. Statistical
significance was set at the 95 % confidence level (p \ 0.05).
3 Results
Overall, the therapy was tolerated well. No infections were
reported. Back pain and headache were rare. The low rate
of headache may have been due to the fact that TCA sus-
pension dissolved in saline was administered. The results
did not differ significantly between the groups. The
unbalanced design of the study may have limited the
results. The clinical outcomes showed a significantly
improved (p B 0.001) walking distance. On average, the
walking distance improved in all patients from 247 m
(SD 302) to 322 m (SD 346). Spasticity was measured on
the Ashworth Scale and improved significantly (p B 0.001)
during TCA applications from 2.2 (SD 1.3) at baseline to
1.6 (SD 1.1) at the end of the cycle. Further analysis will
be reported separately.
CSF markers were determined during application of
TCA at baseline (the first application of TCA), on day 4
(the third application of TCA), and on day 8 (the fifth
application of TCA). Patients were given TCA three times
(n = 54), though in cases of severe spasticity (n = 26),
TCA was applied five times. Besides the aforementioned
markers of neurodegeneration, the cell count was deter-
mined as part of the routine assessment. Further CSF
analysis revealed a decreasing cell count from 10.8
(SD 18.9) at baseline to 6.3 (SD 6.2) on day 8.
NfHSMI35 levels in the CSF of patients treated with TCA
intrathecally did not increase significantly (baseline level:
0.11 ng/ml [SD 0.11]; level at third application [after two
TCA applications]: 0.14 ng/ml [SD 0.15], p = 0.053; level
at fifth application [after four TCA applications]: 0.16 ng/
ml [SD 0.15], p = 0.068) during the treatment (see Fig. 1).
In all patients, CSF NfHSMI35 levels remained within the
normal range (maximum value 0.58 ng/ml, below the cut-
off of 0.73 ng/ml) [15].
After application of TCA, tau protein levels were increased
significantly on day 4 (from 194.07 pg/ml [SD 82.47] at
baseline to 250.31 pg/ml [SD 168.84], p = 0.03) and on
day 8 (245.54 pg/ml [SD 121.79], p B 0.001) [see Fig. 2].
Fig. 1 Concentration of
NfHSMI35 during the first cycle
of triamcinolone-acetonide
(TCA) therapy. Statistical
analysis: Friedman test,
Wilcoxon test.
NfH neurofilament heavy-chain
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S-100B protein levels decreased significantly over the
complete cycle (from 1.18 mg/l [SD 0.66] at baseline to
1.00 mg/l [SD 0.44] on day 8, p B 0.05). The effect could
already be seen by day 4 (1.01 [SD 0.46], p B 0.05) [see
Fig. 3].
The results for NfHSMI35, tau protein, and S-100B did
not differ significantly between the relapsing MS–remitting
MS patient group and the primary progressive MS patient
group.
4 Discussion
Intrathecal TCA is an efficient therapeutic way to treat
spasticity and spare MS patients the discomfort of wearing
a corset. It has proven its efficacy in a number of trials [24–
26]. In vitro experiments have suggested that GCS has
neurotoxic properties [14, 15, 17].
In our trial, we measured the levels of NfHSMI35, tau
protein, and S-100B protein, which are well accepted as
surrogate markers of axonal injury and degeneration [27],
neuronal damage [20, 28], and activated astroglia, mainly
reflecting parenchymal damage [22, 29].
NfHSMI35, as a surrogate marker of axonal damage, was
measured for the first time in patients receiving TCA
treatment. The results did not reach significance and
remained below the assumed critical value of 0.73 ng/ml.
Neurofilament activity varies between the different stages
of disease and is influenced by clinical activity. In respect
thereof, all of our patients were stable with no relapse for
3 months prior to the first application of TCA and,
although the patients were recruited at different stages of
the disease (relapsing MS and progressive MS), with dif-
fering Expanded Disability Status Scale (EDSS) scores, the
results with regard to NfH did not vary significantly in the
intergroup comparison. This may have been due to the
limited power of the study. Another limitation might be the
fact that only patients with low NfH levels at baseline were
included in the trial. It would have been interesting to see
what would have happened to patients with pathological
NfH levels at baseline.
The level of total tau protein significantly increased in
comparison with baseline. However, the mean value did
not reach the critical value of 300 pg/ml [28]. The question
of to what extent such an increase has clinical implications
remains open. In a study by Hoffmann et al. [10] in 27
patients, TCA was applied six times, and the levels of tau
protein and S-100B did not increase significantly. Research
into the long-term effects of TCA on tau protein levels may
elucidate whether increased levels have further clinical
implications. Currently, the importance of tau protein in
MS patients is not completely understood. To what extent
this increase could have been explained by release of tau
protein from the cytoskeleton of neurons or from glial cells
in our patients remains open. The importance of tau protein
in neuroinflammation and neurodegeneration in MS is not
fully understood. Whereas animal models have suggested a
link between axonal damage and tau pathology [30],
findings elucidating tau protein levels in the CSF of MS
patients have been partly contradictory [31–33].
Fig. 2 Concentration of Tau
protein during the first cycle of
triamcinolone-acetonide (TCA)
therapy. Statistical analysis:
Friedman test, Wilcoxon test
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Besides the increases in tau protein levels (significant)
and NfHSMI35 levels (non-significant), a decrease in
S-100B levels was observed. Reduced astrocytic activity
during TCA treatment may be due to corticosteroid-medi-
ated immunosuppressive effects on microglial activation.
As a result, the levels of interleukin-1 might decrease and
lead to minor astroglial activation [34]. However, in vitro
studies have shown that adrenocorticotropic hormone is
responsible for increased secretion of S-100B [35]. At
present, this phenomenon is not understood in detail. The
neurotoxic and neuroprotective effects of S-100B protein
have been discussed previously [36].
To understand the effects of TCA on astrocytic prolif-
eration, further assessments are necessary. The effects of
GCS on neuronal cells and on neuronal activity have been
evaluated. A dose-dependent excitatory effect of methyl-
prednisolone on cultured neuronal networks could be
demonstrable [37, 38].
5 Conclusion
Intrathecal TCA therapy seems to be efficient and well
tolerated for the treatment of symptoms in MS patients.
Future treatment trials may investigate whether, in addition
to symptomatic effects, TCA can reduce the inflammatory
component of glia in the setting of severe transverse
myelitis in MS and possibly also neuromyelitis optica
spectrum disorders, and thus improve the clinical outcome.
Neurotoxic side effects of GCS treatments have been
discussed for decades. The results of our study did not
show neurotoxic effects; the levels of tau protein increased
significantly but remained within the reference range. In
addition, the level of S-100B protein decreased signifi-
cantly during the first applications. Future long-term
studies are needed to clarify the neurotoxic effects of TCA
treatment.
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